Výsledky vyhledávání - "Valorie F. Chan"

Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

Autor: David Miles, José Baselga, Adam Knott, Seock-Ah Im, Valorie F. Chan, Graham Ross, Young-Hyuck Im, Sandra M. Swain, Emma Clark

Publikováno v: The Oncologist. 19:693-701

Introduction. We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708187132f566a90bbefb4e41dd6cc15
https://doi.org/10.1634/theoncologist.2014-0033

Zobrazit plný text záznamu

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)

Autor: Nagahiro Saijo, Rose McCormack, Kazuhiko Nakagawa, Gael McWalter, Yi-Long Wu, Valorie F. Chan, James Chih-Hsin Yang, Johan Kurnianda, Masahiro Fukuoka, Tony Mok

Publikováno v: Lung Cancer. 83:174-181

ObjectivesEpidermal growth factor receptor (EGFR) mutation testing is standard practice after lung adenocarcinoma diagnosis, and provision of high-quality tumor tissue is ideal. However, there are knowledge gaps regarding the utility of cytology or l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791d0feeec1b2a03d5dc8d9befccc619
https://doi.org/10.1016/j.lungcan.2013.11.021

Zobrazit plný text záznamu

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Autor: Pralay Mukhopadyay, Jacek Jassem, Fernando Hurtado de Mendoza, Eva Thomas, Hyun Cheol Chung, Henri Roché, Valorie F. Chan, Rubi K. Li, Luis Fein, Xavier Pivot

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2009, 45 (17), pp.2940-6. ⟨10.1016/j.ejca.2009.07.015⟩

International audience; Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47efabd05a6e46cffb7bbcb8a7f6b9af
https://doi.org/10.1016/j.ejca.2009.07.015

Zobrazit plný text záznamu

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

Autor: Raymond P. Abratt, Johann Raats, Fiona H Blackhall, Johan Vansteenkiste, Filippo de Marinis, Peter Langmuir, Jessica Read, Richard De Boer, Jürgen Wolf, Tsveta Milenkova, Chih-Hsin Yang, Valorie F. Chan, Maya Gottfried, Oscar Arrieta

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(8)

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2041ba326af59a4e2bb9a7647608a636
https://pubmed.ncbi.nlm.nih.gov/21282537

Zobrazit plný text záznamu

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Autor: Henri Roché, Linda T. Vahdat, Pralay Mukhopadhyay, Xavier Pivot, Valorie F. Chan, Guillermo Lerzo, Fernando Hurtado de Mendoza, Luis Fein, Ronald Peck, Gabriel N. Hortobagyi, Rubi K. Li, Jacek Jassem, Hyun Cheol Chung, Binghe Xu, Henry L. Gomez

Publikováno v: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2010, 122 (2), pp.409-18. ⟨10.1007/s10549-010-0901-4⟩

Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment. Ixabepilone, a novel semisynthetic analog of epothilone B, has demonstrated single-agent activity in MBC resistan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c712ebc24fb4dfb84dc2bc3a4c9184
https://www.hal.inserm.fr/inserm-00508112

Zobrazit plný text záznamu

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Autor: Xavier Pivot, Linda T. Vahdat, Mario Campone, Binghe Xu, Pralay Mukhopadhyay, Hyun Cheol Chung, Henri Roché, Eva Thomas, Rubi K. Li, Valorie F. Chan, Henry L. Gomez, Fernando Hurtado de Mendoza, Jacek Jassem, Luis Fein, J. Klimovsky, Guillermo Lerzo, Ronald Peck

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2007, 25 (33), pp.5210-7. ⟨10.1200/JCO.2007.12.6557⟩

Purpose Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e605f277395850fd2b3957240ab60bd3
https://www.hal.inserm.fr/inserm-00479740

Zobrazit plný text záznamu

Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis

Autor: Valorie F. Chan, Antonio Villalon

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 12(1)

To establish whether the combination of a corticosteroid (dexamethasone) and the newer serotonin-3 (5-HT(3)) receptor antagonist ramosetron is superior to ramosetron alone in controlling cisplatin-induced emesis.A total of 283 patients aged 18-75 yea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5125250fcfad80da7bfa834c68851ba9
https://pubmed.ncbi.nlm.nih.gov/14655041

Zobrazit plný text záznamu

Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial

Autor: Arlene Chan, E. Rappold, Binghe Xu, Paul E. Goss, Valorie F. Chan, Dianne M. Finkelstein, V J Harvey, Vinod Raina, Henry L. Gomez, Yanin Chavarri Guerra, Tomomi Kaneko, Katarína Petráková, Yingjie Huang, Keun Seok Lee, Minish Mahendra Jain

Publikováno v: Journal of Clinical Oncology. 31:628-628

628 Background: Benefit from trastuzumab (T) in patients (pts) with HER2–ve tumors by central laboratory FISH testing was shown in an exploratory analysis of the NSABP B-31trial and confirmed by levels of expression of HER2 mRNA. DNA sequencing stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03d3a912e33be8853a8ae84830052c0a
https://doi.org/10.1200/jco.2013.31.15_suppl.628

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání